@article{e3216e8bc81b400ead0e6dfb6376dc1d,
title = "Efficacy and Safety of Retaspimycin Hydrochloride (IPI-504) in Combination with Trastuzumab in Patients (pts) with Pretreated, Locally Advanced or Metastatic HER2-positive Breast Cancer",
author = "Reshma Mahtani and S. Modi and C. Saura and Henderson, \{C. A.\} and Lin, \{N. U.\} and J. Goddard and E. Rodenas and J. O'Shaughnessy and J. Baselga",
note = "e13550 Background: Phase I studies are a fundamental step in anti-cancer drug development. Prior meta-analysis looking at phase I studies showed an overall response rate (ORR) of 10.6 \% and grade 4 toxicity rate of 14.3 \%, and specifically, patients (pts) with mCRC enrolled in phase I trials had an ORR of 1.3 \%.",
year = "2011",
language = "American English",
volume = "29",
journal = "Journal of Clinical Oncology / American Society of Clinical Oncology (ASCO) Annual Meeting",
}